Litigation
Arbutus Biopharma Corporation et al. v. Moderna, Inc. et al.
settled (on appeal)1:22-cv-00252-JDW
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2022-02-28
- Terminated
- 2026-03-03
Patents at issue (6)
Plaintiffs (2)
Defendants (2)
Summary
Arbutus and Genevant sued Moderna over the Moderna COVID-19 vaccine, originally asserting six patents including US 8,822,668. The '668 patent was dropped during bilateral narrowing before trial. The case settled globally on March 3, 2026, with Moderna consenting to judgment on the four surviving patents, and Moderna later appealed.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).